Skip to content

Evaluating Vertebroplasty and Kyphoplasty for Reducing Trauma-related Fractures

Evaluating Transcutaneous Vertebroplasty and Kyphoplasty for Reducing Trauma-related Fractures: a Randomized Pilot Study Using Catscan Volumetry

Status
Withdrawn
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01402167
Enrollment
0
Registered
2011-07-26
Start date
2014-09-01
Completion date
2016-08-01
Last updated
2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vertebral Body Compression Fractures

Brief summary

The primary objective of this study is to compare the volume of injected ciment (polymethyl methacrylate) between a group of patients treated with vertebroplasty and a group of patients treated via kyphoplasty. Secondary evaluation will compare the restoration of vertebral height, volume and cyphotic angle between the two techniques, as well as extravation of ciment and functional and quality of life aspects related to these techniques.

Interventions

PROCEDUREKyphoplasty

Patients will be treated via a balloon kyphoplasty surgical procedure

PROCEDUREVertebroplasty

Patients will be treated via a transcutaneous vertebroplasty procedure.

Sponsors

Centre Hospitalier Universitaire de Nīmes
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for 3 months of follow-up * Fracture type according to Magerl Classification (1994) must be one of the following: A1, A2.1, A3.1, A3.2 * Cyphose of \>10° * Spinal pain * Vertebral fracture \< 3 weeks old located between D5 and L5 * If fragments in the canal, they must protrude less than 40% * Absence of other lesions, including cancer

Exclusion criteria

* The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * Patient cannot read French * Patient is pregnant or breast feeding * Patient has a fracture on an adjacent vertebra * Patient has a contra-indication for a treatment used in this study * ASA class IV or V * Patient has a neurological deficit * Previous spinal surgery

Design outcomes

Primary

MeasureTime frameDescription
The volume (cm^3) of injected cimentBaseline (Day 0)The volume of injected ciment is measured by catscan extrapolated data.

Secondary

MeasureTime frameDescription
Recovery of vertebral volume (%)Day 1 to Day 7Recovery of vertebral volume relative to theoretical volume based on neighboring vertebra.
Change from baseline of the cyphotic angle (°)Days 1 to 7The number of degrees of change in the cyphotic angle of the corrected vertebra relative to baseline measurement (°)
Change from baseline in vertebral height (mm)Days 1 to 7Change in vertebra height (mm) before and after surgery
Volume of ciment leakage (cm^3)Day 1The volume of ciment leakage will be determined according to catscan data.
Change in Visual Analog Scale (0 to 10) for pain before and after surgeryDay 0 (post-op)Brute change in Visual Analog Scale (0 to 10) for pain before and after surgery
% Change in Visual Analog Scale (0 to 10) for pain before and after surgeryDay 0 (post-op)The percentage change (%) in Visual Analog Scale (0 to 10) for pain before and after surgery
The change in the ODI score before and after surgery3 monthsThe change in the Oswestry Disability Index before and after surgery
The % change in the ODI score before and after surgery3 monthsThe percentage change (%) in the Oswestry Disability Index before and after surgery
Change in SF-36 quality of life score before and after surgery1 monthChange in SF-36 quality of life score before and after surgery
The % change in SF-36 quality of life score before and after surgery1 monthPercentage change (%) in SF-36 quality of life score before and after surgery
Change in FABQ score before and after surgery1 monthChange in the Fear-Avoidance Beliefs Questionnaire score before and after surgery
% Change in FABQ score before and after surgery1 monthPercentage change (%) in the Fear-Avoidance Beliefs Questionnaire score before and after surgery
Change in DPQ score before and after surgery1 monthChange in the Dallas Pain Questionnaire score before and after surgery
% Change in DPQ score before and after surgery3 monthsPercentage change (%) in the Dallas Pain Questionnaire score before and after surgery
Duration of surgery (minutes)Day 0 (day of surgery)Length of operative time (minutes)
Presence / absence of per-operative complicationsDay 0 (day of surgery)Presence / absence of per-operative complications
Presence / absence of post-operative complications1 monthPresence / absence of post-operative complications

Contacts

PRINCIPAL_INVESTIGATORPascal Kouyoumdjian, MD

Centre Hospitalier Universitaire de Nīmes

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026